AvantGuard News

We're pleased to announce that AvantGuard Inc. has been awarded a $350,000 Phase I grant from the National Institutes of Health to develop an antimicrobial treatment for diabetic foot ulcers—one of the most challenging and costly complications of diabetes care.

We're pleased to announce that AvantGuard Inc. has been awarded a $300,000 Phase I grant from the National Institutes of Health to develop a novel treatment for dermatophytosis—the fungal infection responsible for conditions like ringworm, athlete's foot, and jock itch. This funding validates AvantGuard’s innovative approach to a widespread problem that affects millions and represents a global market exceeding $10 billion annually.

We're excited to announce that AvantGuard Inc. has been awarded a $2 million Phase IIB grant from the National Institutes of Health to advance the development of polyvantoin chlorine, our innovative polymer-based disinfectant designed to address antimicrobial-resistant biofilms in healthcare settings. This funding represents a major milestone in our mission to tackle antimicrobial resistance and validates our innovative approach to one of healthcare's most pressing challenges

We tested AvantGuard’s antiseptic compound, polyvantoin chlorine, against some of the most feared pathogens in modern medicine: pan-resistant Candida auris (now Candidozyma auris ) , multidrug-resistant ESKAPE bacteria, and a comprehensive panel of dangerous fungi. The results revealed something remarkable. You might think that an antibiotic-resistant pathogen is somehow tougher and harder for any compound to kill. However, whether the pathogen was resistant or susceptible t

We’re excited to share that Ted Eveleth recently joined Marcus Arredondo on the Scales of Success podcast. This series takes an honest look at what it really takes to build, grow, and sustain successful businesses—beyond the headlines and highlight reels. Ted was honored to contribute his story to this powerful conversation.

Despite aggressive infection control protocols, Candida auris continues to defy traditional disinfection strategies—especially on high-touch hospital surfaces. But a new class of chlorine-based disinfectants may offer a long-overdue breakthrough: Avantamine, a stabilized polymer chloramine, is proving effective where others fail. In this article, we explore why C. auris has become such a resilient and costly threat—and how a next-generation technology like Avantamine is engin

Each year, fungal infections affect up to 1 billion people worldwide. While many of these infections are mild, they can become life-threatening, particularly for individuals with weakened immune systems.  Candida auris (now Candidozyma auris )  is a relatively newly identified fungal infection that has been making headlines due to its ability to spread quickly and cause serious infections. What makes C. auris truly unique is its ability to grow at human body temperature and i

Discover the groundbreaking biocide that combines the pathogen-killing power of chlorine with unmatched safety - Avantamine

Candida auris (now Candidozyma auris ) poses a serious global health threat due to its drug resistance, ability to persist on surfaces, and high mortality rates in infected patients. AvantGuard is tackling this challenge head-on with Avantamine™, a revolutionary chlorine-based compound inspired by the human immune system. Unlike traditional treatments, Avantamine™ offers a three-pronged solution: a powerful liquid antiseptic wash, a long-lasting antifungal ointment, and a re

Join us Wednesday, September 25, at the Westin Copley Place, where our CEO, Ted Eveleth, will showcase our groundbreaking work. The RESI...

We are thrilled to announce that AvantGuard has been named a Semi-Finalist in the 2024 Pepperdine Most Fundable Companies competition! Out of over 2,000 participating companies nationwide, AvantGuard has advanced to the top 100, demonstrating our strong potential and commitment to growth. The Pepperdine Most Fundable Companies competition  is a prestigious annual event that identifies and promotes promising startups. The competition is designed to help early-stage U.S. compan

Join us in celebrating Dr. Carine Nkemngong's latest paper, co-authored with Peter Teska from Diversey , on the critical role of...

We’re thrilled to announce that Ted Eveleth and Michael Newell recently joined Nishith (Nish) Acharya on Equal Innovation’s podcast,  The Source Code . This podcast shines a spotlight on startups making a global impact, and we were honored to share our story. Nish, with his insightful questions and his incredible experience in wound healing from his work at The Gillian Reny Stepping Strong Center for Trauma Innovation at Brigham and Women’s Hospital, made this conversatio

AvantGuard's CEO attended three key medical conferences in May, showcasing commitment to advancing wound care and medical technologies.

AvantGuard is thrilled to share we have been chosen as one of the prestigious Hello Tomorrow Deep Tech Pioneers ! This recognition is a testament to our commitment to transforming the world with innovative solutions, specifically addressing the global challenge of drug-resistant pathogens.   AvantGuard Recognized as a Premier Project: Out of an impressive 4,500 applications from 120 countries, AvantGuard emerged as one of the most promising projects in the realm of deep tech.

AvantGuard, a leading pioneer in antimicrobial solutions, was thrilled to have our CEO, Ted Eveleth, participate in the New York State Innovation Summit , on October 16-17, 2023, at the Saratoga City Center . This event brought together visionaries, industry experts, and innovators to explore groundbreaking technologies driving business growth and fostering collaboration. We are grateful to have been part of this summit, underscoring our commitment to advancing science and cr

We are thrilled to announce that AvantGuard has been recognized as a key player in the global Surface Disinfectants market by IMIR Market Research Pvt. Ltd. , a leading global market research and consulting company. According to the latest report, the Surface Disinfectants market is projected to reach USD 6,422.42 Million by 2028, with a remarkable 5.3% Compound Annual Growth Rate (CAGR). This recognition is a testament to AvantGuard's commitment to innovation and excellence

In the bustling landscape of innovation, AvantGuard emerged as a beacon of groundbreaking technology at this year's TechCrunch Disrupt 2023 . Handpicked from thousands of contenders, we proudly stood among the 200 startups showcased at the esteemed Startup Battlefield. This annual event is renowned for unveiling revolutionary startups and discussing the forefront of tech innovation. AvantGuard's journey was nothing short of remarkable. At the heart of our presentation was Ava

Image Credits: Christine Hall, TechCrunch / AvantGuard CEO, Edward “Ted” Eveleth AvantGuard's journey at TechCrunch Disrupt 2023 was nothing short of amazing! Ted Eveleth, AvantGuard's CEO, showcased the groundbreaking antimicrobial technology, which turns chlorine into the ultimate surface protectant. Covered in TechCrunch's article is exactly what AvantGuard is doing differently than your average chlorine-based disinfectant. Beyond surfaces, this innovative polymer has a w

Image courtesy of the National Institute of Allergy and Infectious Diseases Nosocomial infections, commonly know as healthcare associated infections (HAIs) strike 1 in 31 hospital patients daily, but we can fight back! AvantGuard’s Ted Eveleth breaks it down in his latest article on Medical Design & Outsourcing. The article takes an in depth look at: The challenges and importance of preventing infections linked to medical devices in healthcare settings The role of antimicrobi